Common use of Buyer Preamble Clause in Contracts

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(i) Buyer Indemnitees 10.2 Buyer Intermediate Inventory 6.9A Cap 10.4(b) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(i) Claim 10.5(a) Claim Notice 10.5(a) Closing 3.1 Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(h) Competitive Activity 6.5(a) Confidential Information 6.4(c) Confidentiality Agreement 6.4(d) Conveyance Taxes 7.4 Covenant 10.1(a)(iv) Data Room 5.8 De Minimis Threshold 10.4(a)(i) Deductible 10.4(a)(ii) Deferred Assigned Contracts 2.6(a) Deferred Assigned Contract Transfer Date 2.6(b) Direct Claim 10.5(a) Disclosure Schedules Article 4 Disparaging Remarks 6.5(c) Domain Name Transfer Agreement 3.2(a)(v) Effective Time 3.1 Excluded Liabilities 2.4 Excluded Taxes 2.4(d) Exclusivity Period 6.5(a) Existing Stock 9.1(b) Financial Statements 4.5(a) ICON 3.3 Indemnified Party 10.5(a) Indemnifying Party 10.5(a) Intellectual Property Assignment Agreement 3.2(a)(iv) Intermediate 6.9A IP License 4.7(a)(xi) Licensees 9.1(c) Material Contracts 4.7(a) Material Permit 4.9(c)

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(iPlan 5.1(b) Buyer Indemnitees 10.2 Buyer Intermediate Inventory 6.9A Cap 10.4(b) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(i) Claim 10.5(a) Claim Notice 10.5(aRepresentatives 4.9 Closing 2.2(a) Closing 3.1 Balance Sheet 2.3(b)(i) Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(h2.2(a) Competitive Activity 6.5(aClosing Statement 2.3(b)(i) Confidential Information 6.4(c) Company Preamble Company Securities Recitals Confidentiality Agreement 6.4(d5.2 Contribution Recitals Conversion Recitals Covered Matter 7.10 Disclosure Schedule Article III Dispute Notice 2.3(b)(ii) Conveyance Taxes 7.4 Covenant 10.1(a)(ivDisputed Item 2.3(b)(ii) Data Room 5.8 De Minimis Threshold 10.4(a)(i) Deductible 10.4(a)(ii) Deferred Assigned Contracts 2.6(a) Deferred Assigned Contract Transfer Date 2.6(b) Direct Claim 10.5(a) Disclosure Schedules Article 4 Disparaging Remarks 6.5(c) Domain Name Transfer Agreement 3.2(a)(vDFARS 3.28(x) Effective Time 3.1 Excluded Liabilities 2.4 Excluded Taxes 2.4(d2.2(a) Exclusivity Period 6.5(aEnvironmental Permits 3.17(a) Existing Stock 9.1(bEscrow Account 2.2(b)(ii)(B) Escrow Agent 2.2(b)(ii)(B) Escrow Agreement 2.2(b)(ii)(B) Estimated Closing Balance Sheet 2.3(a) Estimated Closing Statement 2.3(a) Estimated Purchase Price 2.3(a) FARS 3.28(x) Financial Statements 4.5(a3.6 Independent Accountant 2.3(b)(ii) ICON 3.3 Indemnified Party 10.5(aLatest Balance Sheet 3.6 Term Section New LLC Recitals NISPOM 3.28(x) Indemnifying Party 10.5(a) Intellectual Property Assignment Agreement 3.2(a)(iv) Intermediate 6.9A IP License 4.7(a)(xi) Licensees 9.1(cOCI 3.28(x) Material Contracts 4.7(a3.12(a) Material Permit 4.9(cPost-Closing Representation 7.15 Purchase Price 2.1 PWC 1.1 Real Property Leases 3.10 Released Parties 7.16 Releasing Parties 7.16 Relevant Persons 3.16(b) Resolution Period 2.3(b)(ii) Seller Group 7.15 Seller Prepared Returns 5.4(a)(i) Sellers’ Representatives 3.27 Solvent 4.7 Tax Allocation Schedule Methodology 5.4(g)(ii) Tax Claim 5.4(e) Transfer Taxes 5.4(d) Unresolved Items 2.3(b)(ii) Waiving Parties 7.15 WARN 5.1(d)

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(iControlled Claims 9.5(a) Buyer Indemnitees 10.2 Buyer Intermediate Inventory 6.9A Cap 10.4(b) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(i) Claim 10.5(a) Claim Notice 10.5(a) Losses 9.2 Closing 3.1 8.1 Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(h8.1 Closing Date Financial Certificate 2.4 Company Preamble Company Contracts 3.12(a) Competitive Activity 6.5(aCompany Real Property 3.9(a) Confidential Information 6.4(c7.8(b) Confidentiality Agreement 6.4(dContinuation Period 7.3(a) Conveyance Taxes 7.4 Covenant 10.1(a)(ivContinuing Employee 7.3(a) Data Room 5.8 De Minimis Threshold 10.4(a)(i1.3(c) Deductible 10.4(a)(iiAmount 9.6(a) Deferred Assigned Contracts 2.6(aEmployment Agreement 8.2(c) Deferred Assigned Contract Transfer Date 2.6(bEnvironmental Threshold Amount 9.6(c) Direct Claim 10.5(a) Disclosure Schedules Article 4 Disparaging Remarks 6.5(c) Domain Name Transfer Agreement 3.2(a)(v) Effective Time 3.1 Excluded Liabilities Estimated Working Capital 2.4 Excluded Taxes 2.4(dFacilities 7.7(a) Exclusivity Period 6.5(a) Existing Stock 9.1(bFinal Working Capital Statement 2.5(e) Financial Statements 4.5(a3.6(a) ICON 3.3 Indemnified Party 10.5(aHolding Period 7.1(b) ICE 3.17(h) Indemnifying Party 10.5(a9.5(a) Intellectual Lease 3.9(b) Leased Real Property Assignment Agreement 3.2(a)(iv3.9(a) Intermediate 6.9A IP License 4.7(a)(xiMajor Customers 3.21(a) Licensees 9.1(cMajor Suppliers 3.21(b) Material Contracts 4.7(aMake-Whole Payment 7.1(c) Material Permit 4.9(cNew Plans 7.3(b) New Welfare Plans 7.3(b) Notice of Disagreement 2.5(c) Old Plans 7.3(b) Owned Real Property 3.9(a) Parties Preamble Party Preamble Per Diem Taxes 7.2(b) Preliminary Working Capital Statement 2.5(b) Purchase Price 2.2 Purchase Price Adjustment 2.5(a) Redemption Date 7.1(b) Sale Price 7.1(c) Securities Act 5.6(a) Seller Preamble Seller Losses 9.3 Senior Notes Transfer 2.3(b) Shares Recitals Straddle Period 7.2(b) Terminated Employee 7.3(a) Third Party Claim 9.5(a) Transfer Tax Returns 7.2(c)

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(i9.1(a) Buyer Indemnitees 10.2 Buyer Intermediate Inventory 6.9A Indemnified Parties 9.2 Cap 10.4(b9.5(a)(i) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(iCash Date 6.9(a) CEE Preamble Claim 10.5(a) Claim Notice 10.5(aInformation 9.4(a) Closing 3.1 2.2(a) Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(h2.2(a) Competitive Activity 6.5(aCoeur Preamble Company Preamble Company Disclosure Schedules Article IV Company IP 4.17 Company/Sellers Fundamental Representations 9.1(a) Confidential Information 6.4(cConditions Satisfied Date 8.2(k) Confidentiality Agreement 6.4(d6.5 Contracts 4.12(a) Conveyance Taxes 7.4 Covenant 10.1(a)(ivCredit Agreement Guaranty 6.13(a) Data Room 5.8 De Minimis Threshold 10.4(a)(iCSA Preamble Designation Period 6.18 Environmental Laws 4.11(f)(i) Deductible 10.4(a)(ii) Deferred Assigned Contracts 2.6(a) Deferred Assigned Contract Transfer Date 2.6(b) Direct Claim 10.5(a) Disclosure Schedules Article 4 Disparaging Remarks 6.5(c) Domain Name Transfer Agreement 3.2(a)(v) Effective Time 3.1 Excluded Liabilities 2.4 Excluded Taxes 2.4(d) Exclusivity Period 6.5(a) Existing Stock 9.1(bEnvironmental Permits 4.11(f)(ii) Financial Statements 4.5(a4.15(a) ICON 3.3 Hazardous Materials 4.11(f)(iii) Indemnified Party 10.5(a9.4(a) Indemnifying Party 10.5(a9.4(a) Intellectual Property Assignment Agreement 3.2(a)(ivInterim Financial Statements 4.15(a) Intermediate 6.9A IP License 4.7(a)(xi) Licensees 9.1(cManquiri Refinancing 6.13(a) Material Contracts 4.7(a4.12(a) Material Permit 4.9(c)Mineral Rights Agreements 4.9(a) Nominee Shareholders 6.18 Permits 4.7(b) Post-Closing Cash Certificate 6.9(b) Pre-Closing Cash Certificate 6.9(a) Release 4.11(f)(iv) Securities Act 5.5 Seller Indemnified Parties 9.3 Seller Reclamation Amount 6.12(a) Sellers Preamble Shares Recitals Specified Litigation Matters 9.2(b) Specified Tax Matters 1.1 Termination Date 10.1(c) Third Party Claim 9.4(a) Transfer Taxes 7.3 VAT Payment Amounts 6.10 VAT Refunds 6.10

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(iDeductible Amount 8.5(a) Buyer Indemnitees 10.2 Group 1.1 (Material Adverse Effect) Buyer Intermediate Inventory 6.9A Indemnified Party 8.2 Buyer Survival Date 8.1(b) Buyer Termination Fee 10.2(b) Canadian Transfer Taxes 9.3 Cap 10.4(b8.3(b) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(iCERCLA 1.1 (Environmental Laws) Claim 10.5(aControl 1.1 (Affiliate) Claim Notice 10.5(a8.7(a) Claim Threshold Amount 8.3(a) Claims 3.1(g) Closing 3.1 7.1 Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(h7.1 Collective Benefits Arrangements 3.1(n)(i)(D) Competitive Activity 6.5(a) Confidential Information 6.4(c) Confidentiality Agreement 6.4(dCompany Recitals Company Shares Recitals Controlling Party 9.9(c) Conveyance Taxes 7.4 Covenant 10.1(a)(ivAgreement 3.1(i)(D) Data Room 5.8 De Minimis Threshold 10.4(a)(iConveyance Property 3.1(i)(D) Deductible 10.4(a)(iiCovered Employee 5.11(b) Deferred Assigned Contracts 2.6(aCure Period 10.1(b)(i) Deferred Assigned Contract Transfer Date 2.6(bDebt Financing 3.2(g) Direct Claim 10.5(aDebt Financing Commitment Letter 3.2(g) Disclosure Schedules Article 4 Disparaging Remarks 6.5(cDebt Receipt Failure 10.2(b) Domain Name Transfer Agreement 3.2(a)(vDisclosed Matters 1.1 (Material Adverse Effect) Effective Time 3.1 Excluded Liabilities 2.4 Excluded Taxes 2.4(dDispute Notice 8.7(b) Exclusivity Period 6.5(aDOJ 5.4(b) Equity Commitment Letter 3.2(g) Equity Financing 3.2(g) Existing Stock 9.1(bCredit Facilities 4.1(h) Extraordinary Transaction 1.1 (Excluded Taxes) Financing Commitments 3.2(g) Financial Statements 4.5(a3.1(e)(i) ICON 3.3 FTC 5.4(b) Indemnifiable Tax 9.9(a) Indemnified Party 10.5(a8.7(a) Indemnifying Party 10.5(aIndemnitor 8.7(b) Intellectual Property Assignment Agreement 3.2(a)(iv) Intermediate 6.9A IP License 4.7(a)(xi) Licensees 9.1(c) Material Contracts 4.7(a) Material Permit 4.9(c)Losses 8.2

Buyer Preamble. Buyer Fundamental Representations 10.1(a)(i) Buyer Indemnitees 10.2 9.2 Buyer Intermediate Inventory 6.9A Losses 9.2 Cap 10.4(b) Cidara CMO 6.9A Cidara CMO Agreement 6.9A CLA/CSA Novation Agreement 3.2(a)(i) Claim 10.5(aAmounts 9.5(b) Claim Notice 10.5(a9.4(a) Claimed Amount 9.4(a) Closing 3.1 ARTICLE III Closing Balance Sheet 2.6(a) Closing Net Working Capital 2.6(a) Closing Date 3.1 Comparator Drug and Placebo Clinical Supplies Schedule 2.1(hARTICLE III Code 2.5 Company Preamble Company Indemnitees 9.3 Company Intellectual Property 4.12 Company Losses 9.3 Contested Amount 9.4(c) Competitive Activity 6.5(a) Confidential Information 6.4(c) Confidentiality Agreement 6.4(d) Conveyance Taxes 7.4 Covenant 10.1(a)(iv) Data Room 5.8 De Minimis Threshold 10.4(a)(i) Deductible 10.4(a)(ii) Deferred Assigned Contracts 2.6(a) Deferred Assigned Contract Transfer Date 2.6(b) Direct Claim 10.5(a) Default 4.14 Disclosure Schedules Article 4 Disparaging Remarks 6.5(cARTICLE IV (Preamble) Domain Name Transfer Agreement 3.2(a)(v) Effective Time 3.1 Excluded Liabilities 2.4 Excluded Taxes 2.4(d) Exclusivity Period 6.5(a) Existing Stock 9.1(b) Financial Statements 4.5(a) ICON 3.3 Indemnified Party 10.5(aEPA 4.19 Hired Employee 6.2(a) Indemnifying Party 10.5(a9.4(a) Intellectual Property Assignment Indemnitees 9.3 Large Customers 4.15 Large Suppliers 4.15 Legal Requirement 4.16(b) Losses 9.3 Most Recent Financial Statements 4.5 Necessary Permits 4.16(a) Non-Solicitation Period 6.1(e) Notice of Disagreement 2.6(a) Parent Preamble PCBs 4.19 Plan/Plans 4.17 Purchased Assets 2.1 Purchase Price 2.4 Real Estate Purchase and Sale Agreement 3.2(a)(iv2.8 Response Notice 9.4(b) Intermediate 6.9A IP License 4.7(a)(xiRestricted Party 6.1(e) Licensees 9.1(cRetained Assets 2.2 Retained Liabilities 2.3 Xxxxxxx Boulevard Properties 2.8 Straddle Periods 10.8(a) Material Contracts 4.7(a) Material Permit 4.9(cTEI Preamble Transfer Taxes 10.8(b)